Jakob Dupont - 12 Dec 2025 Form 4 Insider Report for Bolt Biotherapeutics, Inc. (BOLT)

Role
Director
Signature
/s/ William P. Quinn, Attorney-in-Fact
Issuer symbol
BOLT
Transactions as of
12 Dec 2025
Net transactions value
$0
Form type
4
Filing time
16 Dec 2025, 17:15:09 UTC
Previous filing
02 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Dupont Jakob Director C/O BOLT BIOTHERAPEUTICS, INC., 900 CHESAPEAKE DRIVE, REDWOOD CITY /s/ William P. Quinn, Attorney-in-Fact 16 Dec 2025 0001553335

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BOLT Director Stock Option (Right to Buy) Award +2,500 2,500 12 Dec 2025 Common Stock 2,500 $5.44 Direct F1, F2
transaction BOLT Director Stock Option (Right to Buy) Disposed to Issuer -2,500 -100% 0 12 Dec 2025 Common Stock 2,500 $13.60 Direct F1, F2
transaction BOLT Director Stock Option (Right to Buy) Award +849 849 12 Dec 2025 Common Stock 849 $5.44 Direct F3, F4
transaction BOLT Director Stock Option (Right to Buy) Disposed to Issuer -849 -100% 0 12 Dec 2025 Common Stock 849 $13.60 Direct F3, F4
transaction BOLT Director Stock Option (Right to Buy) Award +1,000 1,000 12 Dec 2025 Common Stock 1,000 $5.44 Direct F3, F5
transaction BOLT Director Stock Option (Right to Buy) Disposed to Issuer -1,000 -100% 0 12 Dec 2025 Common Stock 1,000 $7.02 Direct F3, F5
transaction BOLT Director Stock Option (Right to Buy) Award +1,100 1,100 12 Dec 2025 Common Stock 1,100 $5.44 Direct F6, F7
transaction BOLT Director Stock Option (Right to Buy) Disposed to Issuer -1,100 -100% 0 12 Dec 2025 Common Stock 1,100 $6.40 Direct F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the shares will vest upon the Reporting Person completing each month of continuous service following September 3, 2024; provided, however that the option will vest in full upon a change in control.
F2 The reporting person agreed to cancellation of an option granted on September 3, 2024, in exchange for a new option having a lower exercise price.
F3 The option is fully vested and exercisable.
F4 The reporting person agreed to cancellation of an option granted on September 3, 2024, in exchange for a new option having a lower exercise price.
F5 The reporting person agreed to cancellation of an option granted on May 1, 2025, in exchange for a new option having a lower exercise price.
F6 The shares subject to the option will vest on the earlier of May 27, 2026 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.
F7 The reporting person agreed to cancellation of an option granted on May 27, 2025, in exchange for a new option having a lower exercise price.